Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 271

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

Open access
Van Mieghem, Nicolas M., Unverdorben, Martin, Hengstenberg, Christian, Möllmann, Helge, Mehran, Roxana, López-Otero, Diego, Nombela-Franco, Luis, Moreno, Raul, Nordbeck, Peter, Thiele, Holger, Lang, Irene, Zamorano, José L., Shawl, Fayaz, Yamamoto, Masanori, Watanabe, Yusuke, Hayashida, Kentaro, Hambrecht, Rainer, Meincke, Felix, Vranckx, Pascal, Jin, James, Boersma, Eric, Rodés-Cabau, Josep, Ohlmann, Patrick, Capranzano, Piera, Kim, Hyo-Soo, Pilgrim, Thomas, Anderson, Richard, Baber, Usman, Duggal, Anil, Laeis, Petra, Lanz, Hans, Chen, Cathy, Valgimigli, Marco, Veltkamp, Roland, Saito, Shigeru, Dangas, George D. · 2021 · New England Journal of Medicine

Abstract

BACKGROUND: The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied. METHODS: We conducted a multicenter, prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban with vitamin K antagonists in patients with prevalent or incident atrial fibrillation as the indication for oral anticoagulation after successful TAVR. The primary efficacy outcome was a composite of adverse events consisting of death from any cause, myocardial infarction, ischemic stroke, systemic thromboembolism, valve thrombosis, or major bleeding. The primary safety outcome was major bleeding. On the basis of a hierarchical testing plan, the primary efficacy and safety outcomes were tested sequentially for noninferiority, with noninferiority of edoxaban established if the upper boundary of the 95% confidence interval for the hazard ratio did not exceed 1.38. Superiority testing of edoxaban for efficacy would follow if noninferiority and superiority were established for major bleeding. RESULTS: A total of 1426 patients were enrolled (713 in each group). The mean age of the patients was 82.1 years, and 47.5% of the patients were women. Almost all the patients had atrial fibrillation before TAVR. The rate of the composite primary efficacy outcome was 17.3 per 100 person-years in the edoxaban group and 16.5 per 100 person-years in the vitamin K antagonist group (hazard ratio, 1.05; 95% confidence interval [CI], 0.85 to 1.31; P = 0.01 for noninferiority). Rates of major bleeding were 9.7 per 100 person-years and 7.0 per 100 person-years, respectively (hazard ratio, 1.40; 95% CI, 1.03 to 1.91; P = 0.93 for noninferiority); the difference between groups was mainly due to more gastrointestinal bleeding with edoxaban. Rates of death from any cause or stroke were 10.0 per 100 person-years in the edoxaban group and 11.7 per 100 person-years in the vitamin K antagonist group (hazard ratio, 0.85; 95% CI, 0.66 to 1.11). CONCLUSIONS: In patients with mainly prevalent atrial fibrillation who underwent successful TAVR, edoxaban was noninferior to vitamin K antagonists as determined by a hazard ratio margin of 38% for a composite primary outcome of adverse clinical events. The incidence of major bleeding was higher with edoxaban than with vitamin K antagonists. (Funded by Daiichi Sankyo; ENVISAGE-TAVI AF ClinicalTrials.gov number, NCT02943785.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2111016

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 271

Metadata

Authors
Van Mieghem, N. M., Unverdorben, M., Hengstenberg, C., Möllmann, H., Mehran, R., López-Otero, D., Nombela-Franco, L., Moreno, R., Nordbeck, P., Thiele, H., Lang, I., Zamorano, J. L., Shawl, F., Yamamoto, M., Watanabe, Y., Hayashida, K., Hambrecht, R., Meincke, F., Vranckx, P., Jin, J., Boersma, E., Rodés-Cabau, J., Ohlmann, P., Capranzano, P., Kim, H.-S., Pilgrim, T., Anderson, R., Baber, U., Duggal, A., Laeis, P., Lanz, H., Chen, C., Valgimigli, M., Veltkamp, R., Saito, S., & Dangas, G. D.
Venue
New England Journal of Medicine
Published
2021-12-02
Volume
385
Issue
23
Pages
2150-2160
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3195129689
Cited by
271
References
23
FWCI
30.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. https://app.cochat.ai/papers/10.1056/nejmoa2111016
The paper
Van Mieghem, N. M., Unverdorben, M., Hengstenberg, C., Möllmann, H., Mehran, R., López-Otero, D., Nombela-Franco, L., Moreno, R., Nordbeck, P., Thiele, H., Lang, I., Zamorano, J. L., Shawl, F., Yamamoto, M., Watanabe, Y., Hayashida, K., Hambrecht, R., Meincke, F., Vranckx, P., . . . Dangas, G. D. (2021). Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2111016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.